Answers are grounded in this paper and cite their sources.
There are significant differences in the pharmacokinetics of misoprostol administered by vaginal and oral routes that may explain the difference observed in clinical efficacy. Assuming that the pharmacologic effect of misoprostol is related to its concentration in the plasma, our observation of the prolonged serum concentrations in the vaginal group suggests that vaginal administration could be dosed at longer intervals than oral.
No takes yet. Share an insight, caveat, or question.
Zieman et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: